FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
The approval of Apidra for pediatric use is based upon FDA review of a 26-week, phase III, open-label, active control study of Apidra in comparison with insulin lispro, in 572 children and adolescents with type ...